Upside – $ALEC +58% (global AL050 license brings $100M upfront, up to $1.17B in milestones and extends the cash runway into 2029) – $PCVX +55% (VAX-31 OPUS-1 pivotal Phase 3 trial met all prespecified primary endpoints with a safety profile comparable to existing vaccines) – $PTC +36% (agrees to a $205-a-share all-cash takeover valuing its …
Read in context ›Nu Holdings Stock (NU)
Track Nu Holdings stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
NU
Nu Holdings
financial
$16.05
▲ +0.75 (+4.88%) past year
Market Cap
$77.87B
P/E Ratio
21.8x
1Y Return
+4.88%
EPS (TTM)
$0.74
Read the latest TheStreet Pro articles mentioning Nu Holdings, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning NU yet.
Daily Diary Mentions
2 mentionsUpside, Downside Movers in the Morning Upside, Downside Movers in the Morning Upside – $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July) – $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins) – $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material) – $QSI +13% (no clear fresh catalyst identified; unusually large move …
Read in context ›